DPZ-Hauptseite
RSS
Twitter
YouTube
deutschEnglish
Menü mobile menu

Genome Engineering 

Mussolino

 

Dr. Claudio Mussolino

Research Group “Genome Engineering”                           

Institute for Cell and Gene Therapy & Center for Chronic Immunodeficiency at the Center for Translational Cell Research, Medical Center University Freiburg

Claudio Mussolino is a junior group leader at the Center for Chronic Immunodeficiency and the Institute for Cell and Gene Therapy in Freiburg (Germany) since 2012.

He received his PhD in 2009 at the TIGEM, Telethon Institute of Genetics and Medicine, in Napoli (Italy) where he established a mutation-independent approach to treat dominant forms of the blindness disorder Retinitis Pigmentosa using zinc finger-based designer transcription factors.

Currently, Dr Mussolino research focuses on the development of novel and long-term therapeutic strategies for HIV patients. Using TALE- or CRISPR-based effectors Dr Mussolino explores the potential of editing the genome or the epigenome of hematopoietic stem cells or T cells to render them resistant to HIV infection. Additional current projects include the adaptation of these methodologies to other acquired and congenital disorders of the immune system.

We will hear about: Designer epigenetic modifiers (DEMs) as a novel therapeutics to treat HIV infection

  • Exploring the potential of HIV co-receptors silencing to treat HIV infection
  • Epigenome editing is in principle safer as compare to genome editing
  • Transient expression of DEMs leads to inheritable and long term silencing of the target genes
  • DEMs technology is versatile and can be used both to activate or silence the target genes